RxDoctor Payments Data

Stephen Davidson, MD

Hematology & Oncology · Montgomery, ALNPI 1902852171

Payments from drug & device makers

$4,188in general payments, 2019–2025

Across 232 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$515
  • Novartis$419
  • Pfizer$341
  • Exelixis Inc.$236
  • Johnson & Johnson$191
  • Genentech USA, Inc.$187
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,02196%
  • Education$1684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,188 in reported general payments places this provider in the 25th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$68,763
Medicare patients
384
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide111$2,066,715
IbrancePalbociclib28$437,335
PomalystPomalidomide16$356,357
JakafiRuxolitinib Phosphate22$354,754
ImbruvicaIbrutinib19$216,246
StivargaRegorafenib16$198,656
LonsurfTrifluridine/Tipiracil Hcl13$198,345
TasignaNilotinib Hcl15$126,838
Exemestane209$43,100
Abiraterone Acetate14$41,857
XareltoRivaroxaban31$26,932
EliquisApixaban31$19,135
Fentanyl159$15,194
Imatinib Mesylate17$12,663
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen377$10,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$515$2,066,715111 claims
PfizerIbrance, Eliquis$341$456,47059 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$94$356,35716 claims
Incyte CorporationJakafi$72$354,75422 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$85$216,24619 claims
BayerStivarga$11$198,65616 claims
NovartisTasigna$419$126,83815 claims
Johnson & JohnsonXarelto$191$26,93231 claims
Lilly USA, LLCOlanzapine$12$16641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →